Literature DB >> 31850

Periventricular leukomalacia complex.

M L Grunnet.   

Abstract

At autopsy in the past three years, a new complex of CNS lesions has appeared in 54% (50/93) of the brains of premature infant cadavers that have come from our neonatal intensive care unit. This complex consists of necrotizing lesions in the periventricular white matter and in the gray nuclei of the cerebral hemispheres, the hippocampus and subiculum, cerebellar folia and white matter, and basis pontis. This entity is called the periventricular leukomalacia complex, since the distribution of lesions is similar, yet much more severe, than that described by Banker and Larroche in 1962. Clinical studies have indicated that these lesions may be related to long periods of time at high blood oxygen or prolonged periods in which PO2 and pH fluctuated widely.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 31850

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  4 in total

Review 1.  Ischemic and hemorrhagic cerebral lesions of the newborn. Current concepts.

Authors:  F Guzzetta
Journal:  Childs Nerv Syst       Date:  1991-12       Impact factor: 1.475

2.  Frequency and prognostic significance of germinal matrix hemorrhage, periventricular leukomalacia, and pontosubicular necrosis in preterm neonates.

Authors:  K Skullerud; B Westre
Journal:  Acta Neuropathol       Date:  1986       Impact factor: 17.088

3.  Affection of the hippocampal granule cells in pontosubicular neuron necrosis.

Authors:  A Torvik; K Skullerud; S N Andersen; J Hurum; J Maehlen
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

4.  MRI measurements of the pons and cerebellum in children born preterm; associations with the severity of periventricular leukomalacia and perinatal risk factors.

Authors:  M I Argyropoulou; V Xydis; A Drougia; P I Argyropoulou; M Tzoufi; A Bassounas; S Andronikou; S C Efremidis
Journal:  Neuroradiology       Date:  2003-08-27       Impact factor: 2.804

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.